Skip to content

IEMbase 0463: SLC25A3-related mitochondrial phosphate carrier deficiency

Scope

Field Value
IEMbase ID 463
Nosology 11.1.02.01
Gene SLC25A3
External IDs OMIM:610773; ORPHA:91130
Generated mapping UNMAPPED; low candidate 3-Hydroxy-3-Methylglutaryl-CoA_Synthase_Deficiency.yaml
Candidate DisMech targets No exact local target
Review date 2026-07-07

IEMbase phenotype signal

IEMbase represents autosomal recessive SLC25A3-related mitochondrial phosphate carrier deficiency. The biochemical signal is severe neonatal or infantile plasma lactate elevation. Clinical rows include hypertrophic cardiomyopathy, delayed motor development, exercise intolerance, failure to thrive, hypotonia, myopathy, and perinatal or early infantile death. There are no treatment rows.

DisMech phenotype coverage

There is no exact local DisMech target for SLC25A3 mitochondrial phosphate carrier deficiency. No SLC25A3-specific or mitochondrial phosphate carrier deficiency file was identified.

The generated 3-Hydroxy-3-Methylglutaryl-CoA_Synthase_Deficiency.yaml candidate is a false positive. Local HMGCS2 deficiency is a hepatic ketogenesis disorder with hypoketotic metabolic decompensation during fasting or illness. It does not model mitochondrial phosphate transport, cardiomyopathic mitochondrial energy failure, or the SLC25A3 disease entity.

Concordance and completeness

Judgement: true SLC25A3 mitochondrial phosphate carrier deficiency local gap; reject HMG-CoA synthase deficiency as an exact mapping.

The generated candidate shares nonspecific lactate/metabolic-disease vocabulary only. The gene, transporter mechanism, affected mitochondrial process, and cardiomyopathy-dominant phenotype differ.

Curation actions

  • Keep this record unmapped until an SLC25A3 mitochondrial phosphate carrier deficiency target exists.
  • Do not map to 3-Hydroxy-3-Methylglutaryl-CoA_Synthase_Deficiency.yaml.
  • If curated, include SLC25A3, autosomal recessive inheritance, mitochondrial phosphate carrier dysfunction, severe neonatal or infantile lactate elevation, hypertrophic cardiomyopathy, hypotonia, myopathy, exercise intolerance, delayed motor development, failure to thrive, and early death.